Complex Monitoring of Biochemical and Radionuclide Parameters in Patients with Metastatic Renal Cell Carcinoma during Immunotherapy

Figure 4

(a) TGF- content in the serum of 40 mRCC patients before the initiation of immunotherapy with the inclusion of INF- and nivolumab and after 2 months. (b) IL-17A content in the serum of 40 mRCC patients before the initiation of immunotherapy with the inclusion of INF- and nivolumab and after 2 months (in comparison with the parameters of the control group, ).

(a)

(b)